Testosterone and neurobehavioral outcomes in special operations forces military with multiple mild traumatic brain injury
- PMID: 38995807
- PMCID: PMC11612980
- DOI: 10.3233/NRE-230291
Testosterone and neurobehavioral outcomes in special operations forces military with multiple mild traumatic brain injury
Abstract
Background: U.S. Special Operations Forces (SOF) are at increased risk of multiple mild traumatic brain injury (mmTBI). Testosterone was prescribed for several participants in a VA program designed to address sequelae of mmTBI for SOF.
Objective: To determine testosterone prevalence in the Palo Alto VA Intensive Evaluation and Treatment Program (IETP) and observe for association between testosterone and neurobehavioral outcomes.
Methods: A retrospective cohort study included patients in the Palo Alto VA IETP. Sociodemographic data, testosterone blood levels, and neurobehavioral outcomes were collected from medical records.
Results: 55 IETP participants were included: six were testosterone users; the rest were classified as non-users. Testosterone use in this population is 11%, higher than reported national averages in the U.S. Of the 6 testosterone users, 2 (33%) had a formal diagnosis of hypogonadism prior to initiation of testosterone. Neurobehavioral outcome scores between testosterone users and non-users failed to show statistically significant differences, except for the PROMIS pain score, which was higher in the testosterone user population.
Conclusion: The current study did not find an association between mmTBI, testosterone use, or testosterone level and neurobehavioral outcomes. This study highlights a need to further examine the relationship between hypogonadism, mmTBI, SOF culture around testosterone, and the effects of testosterone use in this population.
Keywords: TBI; Traumatic brain injury; hypogonadism; multiple mild traumatic brain injury; neuroendocrine dysfunction; special operations forces; testosterone.
Conflict of interest statement
The authors report no conflicts of interest.
Figures
References
-
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., Yialamas, M. A. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744. 10.1210/jc.2018-00229 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
